Value of contrast-enhanced transrectal ultrasound in evaluating the response of prostate cancer to neoadjuvant hormonal therapy

ZHAO Yunxin; ZHANG Bei; WANG Xiaolian; ZHOU Shihui; CAI Qiuqiong; KANG Huili; SUN Jian; YAO Guanglibr

doi:10.19732/j.cnki.2096-6210.2024.03.016

您当前的位置：

首页 >

文章列表页 >

Value of contrast-enhanced transrectal ultrasound in evaluating the response of prostate cancer to neoadjuvant hormonal therapy

更新时间：2025-12-15

- Value of contrast-enhanced transrectal ultrasound in evaluating the response of prostate cancer to neoadjuvant hormonal therapy
- Vol. 33, Issue 3, Pages: 315-322(2024)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.19732/j.cnki.2096-6210.2024.03.016
  CLC：
- Published Online：19 July 2024，
  
  Published：19 July 2024
- 稿件说明：
移动端阅览
赵云歆,张贝,王晓莲,等. 经直肠超声造影评估前列腺癌新辅助内分泌治疗反应的价值[J]. 肿瘤影像学, 2024, 33(3): 315-322 https://doi.

org/10.19732/j.cnki.2096-6210.2024.03.016
赵云歆,张贝,王晓莲,等. 经直肠超声造影评估前列腺癌新辅助内分泌治疗反应的价值[J]. 肿瘤影像学, 2024, 33(3): 315-322 https://doi. DOI： 10.19732/j.cnki.2096-6210.2024.03.016.

org/10.19732/j.cnki.2096-6210.2024.03.016 DOI：

摘要

目的：

探讨经直肠超声造影（contrast-enhanced transrectal ultrasound）时间-强度曲线（time-intensity curve，TIC）参数评估前列腺癌（prostate cancer，PCa）患者对新辅助内分泌治疗（neoadjuvant hormonal therapy，NHT）的反应程度。

方法：

纳入27例接受NHT的PCa患者的临床资料，根据术后病理学检查结果分为有效组（

=16）和无效组（

=11）。对比两组患者临床病理学特征、治疗前后血清前列腺特异性抗原（prostate-specific antigen，PSA）和CETRUS检查指标及其变化率，以筛选与NHT反应性有关的潜在指标。进一步采用相关性分析评价其在评估患者对NHT反应方面的价值。

结果：

有效组和无效组在临床病理学特征、治疗前的血清PSA和CETRUS检查指标方面的差异无统计学意义（均

＞0.05）。治疗后，仅有效组的TIC曲线下面积（area under curve，AUC）低于无效组（560 dB·s

710 dB·s），其变化率大于无效组（-27.1%

-5.3%）（均

＜0.05）。相关性分析显示AUC变化率与组织学反应评分之间的相关性略高于治疗后AUC（

为-0.690

-0.630）。

结论：

CETRUS TIC参数中，NHT后的AUC及其变化率在评估PCa患者对NHT反应方面具有较好的价值。其中，AUC变化率可能与治疗反应程度更相关。

Abstract

Objective:

To investigate the value of contrast-enhanced transrectal ultrasound (CETRUS) time-intensity curve (TIC) parameters in assessing the response of prostate cancer (PCa) patients to neoadjuvant hormonal therapy (NHT).

Methods:

The

clinical data of 27 PCa patients who received NHT were included. Based on postoperative pathology

patients were divided into the effective (

=16) and ineffective (

=11) groups. Clinical pathological characteristics

serum prostate-specific antigen (PSA) levels

and CETRUS examination parameters and their change rates before and after treatment were compared between the two groups to identify potential indicators related to NHT response. Further

correlation analysis was used to evaluate their value in assessing patient response to NHT.

Results:

No significant differences were observed between the effective and ineffective groups in clinical pathological characteristics

pre-treatment serum PSA levels

and CETRUS parameters (all

＞0.05). After treatment

the area under the TIC (AUC) was lower in the effective group compared to the ineffective group (560 dB·s

710 dB·s)

with a greater change rate (-27.1%

-5.3%) (both

＜0.05). Correlation analysis showed that the AUC change rate had a slightly higher correlation with histological response scores than the post-treatment AUC (

: -0.690

-0.630).

Conclusion:

In CETRUS TIC parameters

the post- treatment AUC and its change rate have a good predictive value for assessing the response of PCa patients to NHT

with the AUC change rate potentially more related to the degree of treatment response. It helps in developing more targeted treatment strategies and improving the treatment outcomes for PCa patients.

关键词

Keywords

references

Views

280

下载量

CNKI被引量

Alert me when the article has been cited

提交

Tools

Publicity Resources

Diagnostic value of PSAD, TRTE combined with mpMRI for prostate cancer in grey area of PSA

Application of contrast-enhanced transrectal ultrasound during follow-up after targeted cryoablation for treating localized prostate cancer

Relationship between metabolic parameters of ¹⁸F-fluorodeoxyglucose PET/CT of bone metastases and serum markers in the patients with prostate cancer

A comparative study of ⁶⁸Ga-TBM-001 PET/CT and ^99mTc-MDP bone scintigraphy in the diagnosis of bone metastases of prostate cancer

Evaluation of prostate cancer across different treatment stages using ¹⁸F-FDG PET imaging

Related Author

WANG Xiaoming

JIN Qing

XU Dongfeng

XIE Shaowei

DONG Baijun

WANG Yanqing

XIA Jianguo

LI Hongli

Related Institution

Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine

Department of Ultrasound, Renji Hospital, Shanghai Jiao Tong University School of Medicine

Department of Nuclear Medicine, Shandong Cancer Hospital Affiliated to Shandong University

Department of Radiotherapy, Shandong Cancer Hospital Affiliated to Shandong University

Shandong Academy of Medicine Sciences

AI问答

⁰